A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03),Tumori Journal

当前位置： X-MOL 学术 › Tumori J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Tumori Journal ( IF 1.9 ) Pub Date : 2022-11-29 , DOI: 10.1177/03008916221138881
Giuseppe Procopio ₁ , Mélanie Claps ₁ , Chiara Pircher ₁ , Luca Porcu ₂ , Pierangela Sepe ₁ , Valentina Guadalupi ₁ , Ugo De Giorgi ₃ , Davide Bimbatti ₄ , Franco Nolè ₅ , Francesco Carrozza ₆ , Sebastiano Buti _{7,

8} , Roberto Iacovelli ₉ , Chiara Ciccarese ₉ , Cristina Masini ₁₀ , Cinzia Baldessari ₁₁ , Laura Doni ₁₂ , Antonio Cusmai ₁₃ , Angela Gernone ₁₄ , Sarah Scagliarini ₁₅ , Sandro Pignata ₁₆ , Filippo de Braud _{1,

17} , Elena Verzoni ₁

Affiliation

Medical Oncology Unit, Fondazione IRCSS Istituto Nazionale dei Tumori di Milano, Milan, Italy.
Methodology for Clinical Research Laboratory, Oncology Department, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.
Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori, Meldola, Italy.
Department of Medical Oncology, Istituto Oncologico Veneto IOV, IRCCS, Padova, Italy.
Medical Oncology Division of Urogenital and Head & Neck Tumours, IEO, European Institute of Oncology IRCCS, Milan.
Department of Medical Oncology, AUSL della Romagna, Ospedale Civile degli Infermi, Faenza, Italy.
Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Department of Medicine and Surgery, University of Parma, Parma, Italy.
Medical Oncology Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Department of Medical Oncology, Arcispedale Santa Maria Nuova, AUSL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Medical Oncology, Department of Oncology and Haematology, AOU Policlinico di Modena, Modena, Italy.
Department of Oncology, Oncology Unit, University Hospital Careggi, Largo Brambilla, Firenze, Italy.
Department of Oncology "Don Tonino Bello", IRCCS "Giovanni Paolo II", Bari, Italy.
University Department of Medical Oncology, Azienda Ospedaliera Policlinico, Bari, Italy.
Department of Oncology, AORN A. Cardarelli, Naples, Italy.
Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Napoli, Italy.
Department of Medical Oncology & Hematology, University of Milan, Milan, Italy.

Background:First-line therapies based on immune-checkpoint inhibitors (ICIs) significantly improved survival of metastatic renal cell carcinoma (mRCC) patients. Cabozantinib was shown to target kin...

中文翻译：